ScreenerHero

IRONDisc Medicine Inc. Common Stock

NAS · US · Healthcare · Biotechnology · discmedicine.com
79.81USD+1.23%Mkt Cap: 3.06B $P/E: —

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hemato…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.06B $
Enterprise Value2.37B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-212.18M $
Revenue/Share—
Last Price79.81 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees165
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.86
PEG—
EV/EBITDA-8.84
EV/Revenue—
P/S—
P/B4.69
EPS (TTM)-6.48
EPS (Forward)-7.26
52W Range
40.0067% of range99.50
52W High99.50 USD
52W Low40.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.68%
ROA-26.30%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-180.39M $
CapEx (TTM)933.00K $
FCF Margin—
FCF Yield-3.84%
Net Debt-656.88M $
Net Debt/EBITDA2.45
Balance Sheet
Debt/Equity0.04
Current Ratio24.14
Quick Ratio23.64
Book Value/Sh16.80 USD
Cash/Share18.70 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateDec 30, 2022
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)101.58 USD
Upside (mean)+27.3%
Target Range79.00 USD – 128.00 USD
$79.00+27.3% to mean$128.00
# Analysts12
Ownership
Shares Out.38.39M
Float32.95M
Insiders7.74%
Institutions114.31%
Short Interest
Short Ratio14.3d
Short % Float22.46%
Short % Out.19.26%
Shares Short7.39M
Short (prev mo.)6.36M
Technical
SMA 5075.37 (+5.9%)
SMA 20074.41 (+7.3%)
Beta2.06
S&P 52W Chg18.16%
Avg Vol (30d)315.63K
Avg Vol (10d)324.94K
Technical Indicators
RSI (14)56.9
MACD1.4011
MACD Signal1.4379
MACD Hist.-0.0368
BB Upper82.51 USD
BB Middle77.96 USD
BB Lower73.40 USD
BB Width11.69%
ATR (14)2.994 USD
Vol Ratio (20d)1.19x